OncoTherapy Science, Inc. (JP:4564)

:4564

4564

OncoTherapy Science

RESEARCH TOOLSreports

Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥19.00 - ¥35.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥9.97B

Enterprise Value¥6.76B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding398,643,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)10.03

Price to Sales (P/S)9.75

P/FCF Ratio-8.97

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Oncology R&DOncoTherapy's explicit focus on oncology using cancer genomics and molecular-targeted approaches creates a durable strategic position. Specialized R&D increases the likelihood of differentiated drug candidates, aligns with a large, structural oncology market, and supports long-term value if clinical progress continues.

Relatively Strong Equity RatioThe company's relatively high equity ratio provides a structural solvency buffer versus more leveraged peers. This improves resilience to funding shocks, allows management to sustain R&D spending without immediate distress, and broadens financing options over a multi-month horizon.

Positive Revenue And EPS GrowthReported mid-single-digit to double-digit revenue and EPS growth indicate improving commercial or milestone-related traction from a low biotech base. If sustained, this trend supports stronger funding alternatives, validates parts of the business model, and helps transition toward more stable operations over several quarters.

Bears Say

Persistent Negative Cash FlowThe company has ongoing negative operating and free cash flow and relies heavily on financing activities. Over months this persistent cash burn constrains runway, forces dilution or additional debt, and limits the firm's ability to scale development programs or fund late-stage trials without clear cash-generation improvements.

Consistent Operational LossesRecurring negative gross and net margins indicate the business has not reached profitable unit economics. For a biotech, prolonged operational losses increase dependence on external capital, raise execution risk, and can delay reinvestment into priority pipelines, impairing long-term competitiveness.

Declining Assets And EquityA trend of shrinking total assets and stockholders' equity reduces financial flexibility and signals cumulative losses or write-downs. This structural deterioration limits collateral for borrowing, increases vulnerability to adverse shocks, and makes sustaining multi-period R&D programs internally more difficult without new capital.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥19.00 and its highest was ¥35.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥9.97B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 280 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 398,643,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.